A cost-effectiveness analysis of rivaroxaban in combination with acetylsalicylic acid (ASA) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events

B. Pinheiro; M. Gouveia; J. Alarcão; R. Ascenção; M. Borges

doi:10.1016/j.jval.2021.11.323

A cost-effectiveness analysis of rivaroxaban in combination with acetylsalicylic acid (ASA) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events

B. Pinheiro
, M. Gouveia
, J. Alarcão
, R. Ascenção
, M. Borges

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	POSB50
Pages (from-to)	S69-S69
Number of pages	1
Journal	Value in Health
Volume	25
Issue number	1
DOIs	https://doi.org/10.1016/j.jval.2021.11.323
Publication status	Published - Jan 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.jval.2021.11.323

CUBE: Católica Lisbon Research Unit in Business and Economics
Machado, F. (PI), Aranda, A. M. (Researcher), Costa, A. I. D. A. (Researcher), Martins, A. P. (Researcher), Bernard, A. (Researcher), Fidalgo, A. (Researcher), Reis, C. (Researcher), Abecassis-Moedas, C. (Researcher), Santos, C. (Researcher), Tran, D. (Researcher), Fernandes, D. (Researcher), Bonfim, D. (Researcher), Schliephake, E. (Researcher), Kalogirou, F. (Researcher), Reis, F. (Researcher), Santos, F. (Researcher), Machado, F. (Researcher), Sguera, F. (Researcher), Cerqueiro, G. (Researcher), Reis, H. (Researcher), Barreto, I. (Researcher), Silva, J. (Researcher), Salvado, J. C. (Researcher), Neves, J. C. D. (Researcher), Gijsbrechts, J. (Researcher), Stahl, J. (Researcher), Guedes, J. C. (Researcher), Faias, J. (Researcher), Wagner, L. (Researcher), Correia, I. (Researcher), Saldanha, M. F. (Researcher), Fontes, J. C. (Researcher), Modesto, L. (Researcher), Meira, M. (Researcher), Matos, M. G. D. (Researcher), Gouveia, M. (Researcher), Kozeniauskas, N. (Researcher), Bertani, N. (Researcher), Couzoff, P. (Researcher), Barroso, P. (Researcher), Encarnação, P. (Researcher), Raposo, P. (Researcher), Teles, P. (Researcher), Bastos, W. (Researcher), Bohnsack, R. (Researcher), Vale, R. C. D. (Researcher), Ferreira, R. (Researcher), Lloyd-Braga, T. (Researcher), Ramus, T. (Researcher), Colaço, V. H. (Researcher), Cavicchini, A. (Researcher), Parada, P. (Researcher), Pieters, R. (Researcher), Pinto, F. S. (Researcher), Colaço, V. H. (Researcher) & Venter, Z. (Researcher)
1/01/20 → 31/12/25
Project: Research

Cite this

Pinheiro, B., Gouveia, M., Alarcão, J., Ascenção, R., & Borges, M. (2022). A cost-effectiveness analysis of rivaroxaban in combination with acetylsalicylic acid (ASA) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. Value in Health, 25(1), S69-S69. Article POSB50. https://doi.org/10.1016/j.jval.2021.11.323

@article{db911d2785ad4f4b9abb48d71d9a4f79,

title = "A cost-effectiveness analysis of rivaroxaban in combination with acetylsalicylic acid (ASA) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events",

author = "B. Pinheiro and M. Gouveia and J. Alarc{\~a}o and R. Ascen{\c c}{\~a}o and M. Borges",

year = "2022",

month = jan,

doi = "10.1016/j.jval.2021.11.323",

language = "English",

volume = "25",

pages = "S69--S69",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Ltd.",

number = "1",

}

Pinheiro, B, Gouveia, M, Alarcão, J, Ascenção, R & Borges, M 2022, 'A cost-effectiveness analysis of rivaroxaban in combination with acetylsalicylic acid (ASA) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events', Value in Health, vol. 25, no. 1, POSB50, pp. S69-S69. https://doi.org/10.1016/j.jval.2021.11.323

A cost-effectiveness analysis of rivaroxaban in combination with acetylsalicylic acid (ASA) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. / Pinheiro, B.; Gouveia, M.; Alarcão, J. et al.
In: Value in Health, Vol. 25, No. 1, POSB50, 01.2022, p. S69-S69.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A cost-effectiveness analysis of rivaroxaban in combination with acetylsalicylic acid (ASA) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events

AU - Pinheiro, B.

AU - Gouveia, M.

AU - Alarcão, J.

AU - Ascenção, R.

AU - Borges, M.

PY - 2022/1

Y1 - 2022/1

U2 - 10.1016/j.jval.2021.11.323

DO - 10.1016/j.jval.2021.11.323

M3 - Meeting Abstract

SN - 1098-3015

VL - 25

SP - S69-S69

JO - Value in Health

JF - Value in Health

IS - 1

M1 - POSB50

ER -

A cost-effectiveness analysis of rivaroxaban in combination with acetylsalicylic acid (ASA) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events

UN SDGs

Access to Document

Projects

CUBE: Católica Lisbon Research Unit in Business and Economics

Cite this